TCTMD

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High ...

The treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial [HeFH]) or mixed dyslipidemia, as an adjunct to diet: in combination with a statin or statin with ...
Medscape

FDA Approves Once-Monthly Cholesterol-Lowering Evolocumab (Repatha) Device

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase subtilisin ...
The American Journal of Managed Care

Repatha Offers Additional LDL-C Reduction in a Convenient Dosage Form

Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused ...
FiercePharma

Critical Milestone for Patients With Uncontrolled Cholesterol who Require Additional Intensive LDL-C Reduction

The recommended dose for adults with primary disease is either 140 mg every two weeks or 420 mg (the contents of three pre-filled syringes) once a month; both doses are clinically equivalent. For ...
Monthly Prescribing Reference

All Repatha Devices Launched at Reduced List Price

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...
The Financial

Positive Efficacy And Tolerability Study Of Repatha In Statin-Intolerant Patients Published In “Journal of the American Medical Association”

The FINANCIAL — Amgen on April 3 announced new detailed data from the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) trial evaluating Repatha ...
Pharmabiz

Amgen makes all Repatha device options available in US at 60% reduced list price

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...
The American Journal of Managed Care

FOURIER Study Finds Repatha Reduces Risk of Cardiovascular Events

Amgen's Repatha was shown to reduce the risk of cardiovascular events, such as cardiovascular death and myocardial infarction, in phase 3 of the FOURIER study. Full results will be presented in March ...
TCTMD

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Approximately 27,500 Patients are Now Fully Enrolled in FOURIER Trial Designed to Evaluate if Repatha in Combination With Statin Therapy Reduces the Risk of Cardiovascular Events. Results From ...
News Medical

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha ® (evolocumab) Injection, the first proprotein ...
FiercePharma

Critical Milestone for Patients With Uncontrolled Cholesterol who Require Additional Intensive LDL-C Reduction

To view the multimedia assets associated with this press release, please click: http://www.multivu.com/players/English/7414052-amgen-repatha/. The EC approved Repatha ...